share_log

HC Wainwright & Co. Initiates Coverage On Zenas BioPharma With Buy Rating, Announces Price Target of $30

HC Wainwright & Co. Initiates Coverage On Zenas BioPharma With Buy Rating, Announces Price Target of $30

HC Wainwright & Co. 開始對Zenas BioPharma進行覆蓋,給予買入評級,並宣佈目標價爲30美元。
Benzinga ·  12/16 20:28  · 評級/大行評級

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Buy rating and announces Price Target of $30.

HC Wainwright & Co. 分析師馬修·考菲爾德開始對澤納斯生物製藥(納斯達克股票代碼:ZBIO)進行報道,評級爲買入,並宣佈目標股價爲30美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論